Shares of Harrow Health (NASDAQ:HROW) soared over 27% on Tuesday. This was attributable to the approval of an anesthesia gel for the surface of the eye, which was developed together with Sintetica.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The gel is patent-protected until 2038 and represents the first branded ocular anesthetic approved in over a decade for the U.S. market.
What is the Price Target for HROW Stock?
HROW has a Moderate Buy consensus rating based on one Buy assigned in the past three months. The HROW stock price target of $17 implies 74.5% upside potential.
